The Journal for ImmunoTherapy of Cancer
is an open access journal that publishes high quality research, literature reviews, position papers and practice guidelines, and case studies on all components of cancer immunology and immunotherapy.
Impact Factor: 10.9
All metrics >>
The Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer-reviewed journal that aims to enrich communication and advance scientific understanding in the rapidly evolving fields of tumor immunology and cancer immunotherapy. Topics of interest range across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity.
JITC is the official journal of the Society for Immunotherapy of Cancer (SITC).
James L. Gulley, MD, PhD, FACP
Michael T. Lotze, MD
SITC 2023 Abstracts
The Journal for ImmunoTherapy of Cancer accepts a variety of article types in a number of formats.
The Author Information section provides specific article requirements and section outlines to help you turn your research into an article suitable for JITC.
Clinical/translational cancer immunotherapy:First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS >=1%: results from a multicenter, open-label, phase 2 trial
22 February 2024
Clinical/translational cancer immunotherapy:Cardiovascular toxicities associated with bispecific T-cell engager therapy
22 February 2024
Immunotherapy biomarkers:Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer
15 February 2024
Correction:Correction: RCAd-LTH-shPD-L1, a double-gene recombinant oncolytic adenovirus with enhanced antitumor immunity, increases lymphocyte infiltration and reshapes the tumor microenvironment
15 February 2024
Immunotherapy biomarkers:Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma
14 February 2024
Most Read Articles
Case report:Spontaneous tumor regression following COVID-19 vaccination
3 March 2022
Position article and guidelines:Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
31 March 2023
Immune cell therapies and immune cell engineering:Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering
14 March 2023
Review:Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells
17 May 2022
Immune cell therapies and immune cell engineering:Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice
10 March 2023
What Our Editors Are Reading
The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC provides members with a 35% discount on Article Processing Charges (APCs) for all JITC articles submitted and accepted in 2023. This discount is applied post-acceptance, at which point a discount code is shared with the corresponding author.
For information on APC discounts and waivers – including those for members, editors or reviewers, low-income countries, or institutional arrangements – view the journal's APC policy.